8-K: Abeona Therapeutics Receives FDA Complete Response Letter for Pz-cel, Citing CMC Data Needs

Abeona Therapeutics received a Complete Response Letter from the FDA for its pz-cel Biologics License Application, requiring additional Chemistry, Manufacturing, and Controls information, but not raising concerns about clinical efficacy or safety.

Summary

• Abeona Therapeutics has received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for pz-cel, a treatment for recessive dystrophic epidermolysis bullosa (RDEB).
• The FDA's CRL is based on the need for additional Chemistry, Manufacturing, and Controls (CMC) information.
• The CRL did not identify any issues with the clinical efficacy or safety data submitted in the BLA.
• The FDA did not request any new clinical trials or clinical data to support the approval of pz-cel.
• Abeona anticipates completing and submitting the requested CMC information in the third quarter of 2024.
• The company had previously submitted plans to the FDA to provide CMC data prior to BLA approval, and full validation reports after approval in mid-2024.
• The FDA indicated that the proposed timing of the data submission would not allow sufficient time for review by the May 25, 2024 PDUFA date.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the CRL, which delays the approval process. However, the lack of clinical concerns and the company's commitment to addressing the issues provide some optimism.

Positives

• The FDA did not raise any concerns about the clinical efficacy or safety data of pz-cel.
• No new clinical trials or clinical data were requested by the FDA.
• Abeona has a clear path forward by addressing the CMC deficiencies.
• The company anticipates completing the BLA resubmission in the third quarter of 2024.
• Pz-cel has been granted Regenerative Medicine Advanced Therapy, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the FDA.

Negatives

• The FDA issued a Complete Response Letter (CRL), delaying the potential approval of pz-cel.
• The CRL was issued due to the need for additional CMC information, specifically validation requirements for certain manufacturing and release testing methods.
• The FDA stated that Abeona's proposed timing of data submission would not allow sufficient time for review by the May 25, 2024 PDUFA date.
• The company was surprised and disappointed by the CRL.

Risks

• The timing and results of ongoing testing and other corrective actions being performed in response to the FDA's identified deficiencies could delay the BLA resubmission.
• The timing and outcome of the FDA's review of the resubmission is uncertain.
• There are risks associated with data analysis and reporting.
• The company faces risks associated with changes in financial markets and global economic conditions.

Future Outlook

Abeona anticipates completing the BLA resubmission in the third quarter of 2024 after addressing the CMC deficiencies outlined in the CRL.

Management Comments

• Vish Seshadri, Chief Executive Officer of Abeona, stated that they are surprised and disappointed by the CRL but are committed to providing the necessary CMC information.
• The CEO also mentioned that they expect all of the FDA's requests to be addressable in a reasonable timeframe.

Industry Context

This announcement highlights the challenges in bringing novel gene therapies to market, particularly in the area of manufacturing and quality control. The need for robust CMC data is a common hurdle in the regulatory approval process for biologics.

Comparison to Industry Standards

• The FDA's focus on CMC data is consistent with industry standards for biologics, where manufacturing processes are critical for product quality and consistency.
• Other companies developing gene therapies have also faced similar challenges in meeting CMC requirements, often leading to delays in regulatory approvals.
• Companies like bluebird bio and Sarepta Therapeutics have experienced similar regulatory hurdles related to manufacturing and quality control in the past.

Stakeholder Impact

• Shareholders may experience a negative impact due to the delay in potential approval of pz-cel.
• Patients with RDEB will experience a delay in access to a potential treatment.
• Employees may face uncertainty due to the regulatory setback.

Next Steps

• Abeona will generate the additional CMC information requested by the FDA.
• The company will resubmit the BLA in the third quarter of 2024.
• Abeona will host a conference call and webcast on April 23, 2024, to provide details on the requested CMC information.

Key Dates

Keywords

pz-cel, FDA, Complete Response Letter, CRL, Biologics License Application, BLA, CMC, Chemistry Manufacturing and Controls, RDEB, recessive dystrophic epidermolysis bullosa, gene therapy, Abeona Therapeutics